Recent, additional data show that the prevalence of adamantane-resistant influenza A viruses is high across the United States, according to a new study published online today by JAMA because of its public health importance. The study will be published in the Feb. 22 print issue of JAMA.
Amantadine and rimantadine are in a class of drugs called adamantanes and have been used as a first-choice antiviral drug against community outbreaks of influenza A viruses for many years. According to the authors of the current JAMA study, rates of viruses resistant to these drugs have been increasing globally and rapid surveillance for the emergence and spread of resistant viruses is critical for the treatment of patients. The authors write that on average, influenza A viruses, a major cause of illness and death in the U.S., infect about 10 15 percent of the population annually. While vaccination is the primary strategy for preventing influenza infections, influenza antiviral drug therapy (such as amantadine and rimantadine) is effective for treating patients with the flu, especially in nursing homes and long term care facilities.
Rick A. Bright, PhD, and colleagues from the CDC, analyzed 209 influenza isolates collected from patients in 26 states from Oct. 1 through Dec. 31, 2005, and tested for drug resistance as part of ongoing surveillance. Of the 209 A (H3N2) viruses screened, we found an alarmingly high adamantane resistance rate of 92 percent, the researchers report. These viruses were isolated from patients residing in 26 states, representing all regions of the United States. This rate was much higher than the rate found among viruses collected within the United States during previous influenza seasons.
Our results highlight the importance of continued surveillance for the emergence and transmission of influenza viruses resistant to antiviral drugs. They serve as a warning to the medical community of the speed at which resistant influenza viruses can become predominant circulating strains and spread throughout a continent, the authors conclude.
In an accompanying editorial, David M. Weinstock, MD, and Gianna Zuccotti, MD, MPH, from Memorial Sloan-Kettering Cancer Center, New York, write, The global burden of influenza infection is staggering. In a typical year, approximately 20 percent of the worlds population is infected and more than a half million individuals die of influenza-associated complications.
They add, The report by Bright and colleagues is a clarion call for action from the medical community. Physicians and other health care professionals must educate patients and communities; organize an international response through governmental and nongovernmental organizations; advocate against the release of over-the-counter antiviral drugs, either directly by major drug companies or through licensing agreements with generic manufacturers; and recognize the powerful influences that affect prescribing practices before assigning culpability to those who have inappropriately used adamantanes.
In conclusion, they write, The response must be global and immediate. If successful, there is some evidence that the prevalence of resistance not only might stabilize, but actually decrease.
Source: American Medical Association